CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Rasburicase +1 moredrug
Likely dose
Rasburicase 7.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00756964
NCT00756964Phase 2Completed
CompareCT.gov

Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.

University of Florida·interventional·Posted Sep 22, 2008·Updated Sep 3, 2012

In Brief

A Phase 2 clinical trial evaluating Rasburicase and Placebo for Hyperuricemia. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Acute kidney injury is associated with a rise in serum uric acid during cardiovascular surgery and can cause poor blood flow to the kidneys making them vulnerable to kidney injury. We hypothesize that hyperuricemia, particularly if chronic and marked, is a risk factor for acute kidney injury. The preoperative lowering of serum uric acid will reduce the incidence of acute kidney injury following cardiovascular surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperuricemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 22, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.8 years ago

Interventions

Rasburicasedrug

Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.

Placebodrug

Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.